Evaluating health conditions in HIV-infected individuals starting treatment
A Prospective Longitudinal Cohort Study to Determine the Incidence of HIV-associated Non-AIDS Conditions in Newly Diagnosed HIV-infected Individuals Initiating Integrase Inhibitor-based and Other Anti-retroviral Regimens
This study is trying to see if different HIV treatments affect the chances of developing health problems like high blood pressure and diabetes in people who are just starting their HIV medication.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Sha Tin) |
| Trial ID | NCT03483584 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the incidence of HIV-associated non-AIDS (HANA) conditions among newly diagnosed HIV-infected individuals in Hong Kong who are beginning anti-retroviral therapy. The study will compare the incidence of various HANA conditions, such as hypertension, diabetes, and osteoporosis, between patients receiving integrase strand transfer inhibitor (INSTI) regimens and those on other non-INSTI regimens. By monitoring these conditions, the study seeks to provide insights into the long-term health management of HIV patients as they live longer due to effective treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are HIV-infected individuals aged 40 and older who are treatment-naïve and agree to start anti-retroviral therapy.
Not a fit: Patients who are pregnant or unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management strategies for HIV-infected individuals, reducing the incidence of serious non-AIDS conditions.
How similar studies have performed: While the study focuses on a specific cohort and conditions, similar studies have indicated the importance of monitoring HANA conditions in HIV patients, suggesting potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Confirmed HIV infection by HIV antibody or RNA test 2. Age ≥40 years old 3. Anti-retroviral treatment naïve 4. Agree to initiate anti-retroviral therapy (ART) as determined by in-charge HIV physician Exclusion Criteria: 1. Pregnancy 2. Unable to give informed consent
Where this trial is running
Sha Tin
- Prince of Wales Hospital — Sha Tin, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Grace Lui — Cuhk
- Study coordinator: Rity Wong
- Email: ritywong@cuhk.edu.hk
- Phone: +85235053376
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.